Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;101(9):e365-8.
doi: 10.3324/haematol.2016.144279. Epub 2016 May 31.

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia

Agnès Charpentier  1 , Aurélien Lebreton  2 , Antoine Rauch  3 , Anne Bauters  4 , Nathalie Trillot  4 , Oliver Nibourel  5 , Véronique Tintillier  4 , Mathieu Wemeau  6 , Jean-Loup Demory  7 , Claude Preudhomme  5 , Brigitte Jude  3 , Thomas Lecompte  8 , Nathalie Cambier  9 , Sophie Susen  10
Affiliations

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia

Agnès Charpentier et al. Haematologica. 2016 Sep.
No abstract available

Keywords: CALR; JAK2; chronic myeloproliferative disorders; microparticles; thrombosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Circulating microparticle counts with respect to the mutational status of ET patients. JAK2: JAK2-V617F mutated patients; CALR: CALR-mutated patients; TN: so-called “triple negative” patients, for which neither the two former mutations, nor a mutation in the MPL gene, were found. *indicates P<0.01, ** indicates P<0.001. In addition to individual data, median values and interquartile ranges are plotted. MPs indicates all annexin V+ events in the gate delineated with dedicated beads (Megamix® beads, BioCytex, Stago, Marseille, France), whatever their cellular origin. Phenotyping was performed by co-labeling with annexin V and lineage-specific antibodies (as detailed in the Online Supplementary Material): RMP: red cell-derived microparticles, MoMP: monocyte-derived microparticles, GMP: granulocyte-derived microparticles, EMP: endothelial cell-derived microparticles, PMP: CD41+ MP, so-called platelet-derived microparticles, P-selectin+ PMP: PMPs coexpressing P-selectin, P-selectin+ PMP % of PMP: percentage of PMPs coexpressing P-selectin among PMPs. MoMPs, GMPs and EMPs were enumerated in a subset of 45 ET patients. Labeling procedure is detailed in the Online Supplementary Material.
Figure 2.
Figure 2.
Relation between MP counts and prothrombotic state in ET patients. Distribution of ET patients according to circulating MPs cutoff value and thrombotic risk assessed with IPSET-thrombosis score. ET patients were distributed between low, intermediate and high thrombotic risk groups. The cutoff value of 4600 MP/μL was calculated by statistical analysis (ROC curve analysis). This value discriminates between high and intermediate or low thrombotic risk patients with a specificity of 81% and a sensitivity of 77%.
See this image and copyright information in PMC

References

    1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–173. - PubMed
    1. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551. - PMC - PubMed
    1. Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015;100(7):893–897. - PMC - PubMed
    1. Gangat N, Wassie EA, Lasho TL, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015;94(1):31–36. - PubMed
    1. Casini A, Fontana P, Lecompte T. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11(7):1215–1227. - PubMed

Publication types